# Observational Study of the Efficacy and Safety of Anlotinib Combined With Penpulimab in Elderly Lung Cancer Patients

> **NCT05319886** · — · UNKNOWN · sponsor: **The First Affiliated Hospital of Xinxiang Medical College** · enrollment: 40 (estimated)

## Conditions studied

- Lung Cancer
- Lung Carcinoma
- Non Small Cell Lung Cancer
- Non-small Cell Carcinoma
- Lung Neoplasm

## Interventions

- **DRUG:** Anlotinib and Penpulimab

## Key facts

- **NCT ID:** NCT05319886
- **Lead sponsor:** The First Affiliated Hospital of Xinxiang Medical College
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-05-16
- **Primary completion:** 2023-03-30
- **Final completion:** 2025-03-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2022-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05319886

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05319886, "Observational Study of the Efficacy and Safety of Anlotinib Combined With Penpulimab in Elderly Lung Cancer Patients". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT05319886. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*